Image For Activity Cover
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure with Preserved Ejection Fraction: PRESERVED-HF (JACC Heart Failure June 2024)

Although sodium glucose co-transporter 2 inhibitors (SGLT2is) improve heart failure (HF)-related symptoms and outcomes in HF with preserved ejection fraction (HFpEF), underlying mechanisms remain unclear. In HF with reduced EF, dapagliflozin altered ketone and fatty acid metabolites vs placebo; however, metabolite signatures of SGLT2is have not been well elucidated in HFpEF.


JACC Heart Failure Editor-in-Chief
Biykem Bozkurt, MD, PhD, FACC 

Deputy Editor
Akshay S. Desai, MD, MPH 

JACC Heart Failure CME/MOC Editor
Kenneth A. Ellenbogen, MD

Bhaskar Arora, MD 

Important Dates

Date of Release: June 10, 2024
Term of Approval/Date of CME/MOC Expiration: June 9, 2025

Availability: On-Demand
Expires on Jun 09, 2025
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
Android App Download IOS App Download Powered By